NewsAvi Kapoor
Tenax Therapeutics
TENX · NASDAQ
$1.63−$0.01 (−0.61%)TodayMarket closed ·
Prev close $1.64
Latest news
- Press releaseGlobe Newswire
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releasePRNewswire
Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky
- Press releaseBusiness Wire
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
- Press releaseBusiness Wire
TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)
- Press releasePRNewswire
TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics
- Press releasePRNewswire
Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX)
- Press releaseGlobe Newswire
Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors: Johnson Fistel Investigates Potential Securities Law Violations After Phase 3 Trial Failure; Shares Plummet Nearly 90%
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsAvi Kapoor
Crude Oil Surges 3%; Sionna Therapeutics Shares Plunge
- NewsVandana Singh
Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback
- NewsAvi Kapoor
US Stocks Edge Lower; Monday.Com Shares Tumble After Q2 Results
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- NewsAvi Kapoor
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
- Press releaseGlobe Newswire
Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
- Press releaseGlobe Newswire
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseGlobe Newswire
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
- Press releaseGlobe Newswire
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releaseGlobe Newswire
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
- Press releaseGlobe Newswire
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releaseGlobe Newswire
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releasePRNewswire
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
- NewsAvi Kapoor
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- News
Market-Moving News for August 6th
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.